Previous 10 | Next 10 |
Gainers: TDCX (NYSE:TDCX) +16%. ALJ Regional Holdings (NASDAQ:ALJJ) +8%. Nxt-ID (NASDAQ:NXTD) +8%. Microvast Holdings (NASDAQ:MVST) +7%. Archer Aviation (NYSE:ACHR) +7%. Losers: SkyWest (NASDAQ:SKYW) -21%. GrafTech International (NYSE:EAF) -9%. Alpine 4 Holdings (NASDAQ:AL...
Gainers: Snap (NYSE:SNAP) +52%. Bill.com Holdings (NYSE:BILL) +31%. Indonesia Energy Corporation (NYSE:INDO) +28%. eGain (NASDAQ:EGAN) +22%. Sphere (NASDAQ:ANY) +21%. Standard Lithium (NYSE:SLI) +17%. Aurora Innovation (NASDAQ:AUR) +17%. Unity Software (NYSE:U) +17%. Astria Therapeutics (NASD...
The following slide deck was published by Astria Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Astria Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
Astria Therapeutics, Inc. (ATXS) Q3 2021 Earnings Conference Call November 10, 2021 8:30 AM ET Company Participants Andrea Matthews - Senior Vice President, Corporate Affairs Jill Milne - Chief Executive Officer Andy Nichols - Chief Scientific Officer Andrew Komjathy - Chief Commercial Office...
Astria TherapeuticS (NASDAQ:ATXS): Q3 GAAP EPS of -$0.61 beats by $0.11. As of September 30, 2021, Astria had cash and cash equivalents of $131.8 million, compared to $139.5 million as of June 30, 2021. The Company expects that it has sufficient cash to fund its current operating plan through...
-- STAR-0215, in Development to Treat HAE, on Track for Initial Phase 1 Clinical Results Expected by Year End 2022 -- -- New Preclinical Data on STAR-0215 Demonstrating High Potency and Extended Plasma Half-Life -- -- Findings on Burdens of Disease and Treatment in HAE...
Astria TherapeuticS (NASDAQ:ATXS) is scheduled to announce Q3 earnings results on Tuesday, November 9th, after market close. The consensus EPS Estimate is -$0.72 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward. For ...
ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program S...
-- STAR-0215 Demonstrates High Potency to Inhibit Plasma Kallikrein Preclinically -- -- Preclinical Data Show STAR-0215’s Extended Plasma Half-Life, Predicting Long Duration of Action -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company ...
News, Short Squeeze, Breakout and More Instantly...
Astria Therapeutics Inc. Company Name:
ATXS Stock Symbol:
NASDAQ Market:
Astria Therapeutics Inc. Website:
2024-06-16 18:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allerg...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Va...